Umbilical cord blood megakaryocyte progenitor cell therapy (Institute Of Field Blood Transfusion, Chinese Academy Of Military Medical Sciences/Beijing Cord Blood Hematopoietic Stem Cell Bank)
脐带血巨核系祖细胞（中国人民解放军军事医学科学院野战输血研究所/北京市脐带血造血干细胞库）
Report date: 2023/02/17 21:03:13
Base Information
Drug NameUmbilical cord blood megakaryocyte progenitor cell therapy (Institute Of Field Blood Transfusion, Chinese Academy Of Military Medical Sciences/Beijing Cord Blood Hematopoietic Stem Cell Bank)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesBeijing Cord Blood Hematopoietic Stem Cell BankInstitute Of Field Blood Transfusion, Chinese Academy Of Military Medical Sciences
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesInstitute Of Field Blood Transfusion, Chinese Academy Of Military Medical SciencesBeijing Cord Blood Hematopoietic Stem Cell Bank
Active IndicationsN/A
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A